Drug Trial Radar · NCT06723392
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,134
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Sep 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- NICHD Global Network for Women's and Children's HealthResearch network
- Sponsor type
- Research network
- Collaborators
- RTI International; University of Virginia; University of Alabama at Birmingham; Thomas Jefferson University; Columbia University; Boston University; University of Colorado, Denver; University of North Carolina, Chapel Hill; International Centre for Diarrhoeal Disease Research, Bangladesh; Kinshasa School of Public Health; Institute of Nutrition of Central America and Panama; Lata Medical Research Foundation, Nagpur; Aga Khan University; University Teaching Hospital, Lusaka, Zambia; KLE Academy of Higher Education and Research (Deemed- to- be-University), Jawaharlal Nehru Medical College (JNMC), Belagavi, India
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study, Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (ABLE), is designed as a 2-arm randomized controlled trial (RCT) focused on pregnant individuals and newborn infants. A positive outcome of this study will contribute to global progress toward WHO Sustainable Development Goal Target 3.2 \[End preventable deaths of newborns and children under 5 years of age\] by examining the potential impact of this practice to reduce the incidence of SVN/SB and the lifelong health consequences associated with SVNs. In addition, the study will further explore the role and potential benefits of antibiotic treatment of AB in the pregnant individual. In total, 1,134 eligible participants, or approximately 162 per research site, will be randomized in the trial by the research teams in each of the seven international sites that, together with their United States of America (US) partners, participate in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's (NICHD's) Global Network for Women's and Children's Health Research (GN).
Conditions
- Preterm Birth
- Small for Gestational Age (SGA)
- Stillbirth
- Bacteriuria (Asymptomatic) in Pregnancy
Interventions
Oral nitrofurantoin monohydrate/macrocrystalsDrug
7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)
PlaceboOther
7-day course of oral placebo 100 mg twice daily (total of 14 doses)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of small vulnerable newborn (SVN) or stillbirth (SB)Time frame: From Pregnancy until 42 days postpartum
Locations
7 sites in 6 countries. Site status is shown where the registry gives one.
Icddr,B
Dhaka, Bangladesh, Bangladesh · Recruiting
Kinshasa School of Public Health
Kinshasa, DRC, Democratic Republic of the Congo · Not yet recruiting
Institue for Nutrition of Central America and Panama (INCAP)
Guatemala City, Departamento de Guatemala, Guatemala · Not yet recruiting
KLE Academy of Higher Education and Research
Belagavi, Karnataka, India · Recruiting
Lata Medical Research Foundation
Nagpur, Maharashtra, India · Not yet recruiting
Aga Khan University
Karachi, Pakistan, Pakistan · Not yet recruiting
University Teaching Hospital
Lusaka, Zambia, Zambia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.